Stemcell United Stock

Stemcell United EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Stemcell United (SCU.AX) as of Sep 8, 2026 is -2.63 M AUD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -1.84 M AUD — a change of 42.85% (lower).

EBITDA

-2.63 MAUD

YoY

42.85%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Stemcell United is 2026 -2.63 M AUD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Stemcell United was 2025 -1.84 M AUD. It decreases by 42.85% lower compared to the previous year.

The Stemcell United EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2015
-1.00 M AUD
Jan 1, 2016
-997,300.00 AUD
Jan 1, 2017
-725,260.00 AUD
Jan 1, 2018
-1.81 M AUD
Jan 1, 2019
-1.52 M AUD
Jan 1, 2020
-1.35 M AUD
Jan 1, 2021
-1.84 M AUD
Jan 1, 2022
-2.63 M AUD
The Stemcell United EBITDA history
YEAREBITDAYoY
-2.63 MAUD+42.85%
-1.84 MAUD+36.51%
-1.35 MAUD-11.32%
-1.52 MAUD-15.65%
-1.81 MAUD+148.95%
-725,260.00AUD-27.28%
-997,300.00AUD-0.50%
-1.00 MAUD—
Access this data via the Eulerpool API
Get Free API Key

Stemcell United Stock analysis

What does Stemcell United do? Stemcell United Ltd is an internationally operating company that is active in the field of stem cell research and therapy. It was founded in 2005 by British entrepreneur and scientist Dr. Samantha Phillips, who previously worked for the renowned Roslin Institute for Animal Genetics. The business model of Stemcell United is based on the development and distribution of innovative therapies that are based on the use of stem cells as a foundation. The company primarily relies on close collaboration with leading research institutions and clinics worldwide to stay up to date with the latest research and develop products and services that are based on current knowledge and meet the highest quality standards. The various divisions of Stemcell United include the development and production of stem cell-based therapies for diseases such as cancer, heart attack, dementia, and stroke. Additionally, the company also offers support and consultation in the field of clinical trials as well as training for doctors and researchers to improve and optimize the use of stem cell therapies. Another important area of Stemcell United's business activities is the production and marketing of stem cells for research purposes. Both embryonic and adult stem cells are produced and provided to advance research in this field and gain new insights. The products offered by Stemcell United mainly include stem cell preparations for wound healing and tissue regeneration, as well as specialized cell cultures for research in the field of stem cell therapy. These products are sold to clinics, research institutions, and end consumers and are available in many countries worldwide. In recent years, Stemcell United has become one of the leading companies in the field of stem cell research and therapy and enjoys a high reputation in the industry. The company primarily relies on close collaboration with other top companies in the industry and a strong connection to research and development in this field. Overall, Stemcell United is an innovative and dynamic company that sets standards in the field of stem cell research and therapy worldwide and constantly seeks new ways to utilize the possibilities of stem cell therapy for the health and well-being of humans and animals. Stemcell United is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Stemcell United stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Stemcell United is -2.63 M AUD in 2026.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Stemcell United changed from -1.84 M AUD to -2.63 M AUD, representing a 42.85% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Stemcell United since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Stemcell United historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Income Statement — Stemcell United

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Stemcell United